drugset / Trial / NCT03938337
Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To assess the objective response rate of tumor lesions to abemaciclib in combination with pembrolizumab in patients with metastatic or recurrent squamous cell carcinoma of head and neck.
Timeline
- Start
- 2019-10-08
- Primary completion
- 2020-04-03
- Completion
- 2020-04-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |